Creating Better Medicines through Better Conjugation

December 16, 2013
Cynthia A. Challener
Cynthia A. Challener

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

BioPharm International, BioPharm International-12-16-2013, Volume 2013 eBook, Issue 1

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.

 

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.

from BioPharm International’s 2013 Innovation Updates and Strategies eBook.